Issuance of the Fifth Series of Stock Compensation-Type Stock Acquisition Rights
First written in FY2018-Q2. 5 of 9 entries say "Advanced", first in FY2018. Latest entry: FY2023.
- FY2023AdvancedAnnual report
「The decrease of 24,000 treasury shares resulted from the exercise of stock acquisition rights for 6,200 shares and the disposal of treasury shares for restricted stock compensation for 17,800 shares.」
The Company disclosed that 6,200 shares of the stock compensation stock acquisition rights, including the 9th Series, were exercised during the period. - FY2022Exercise of the 9th Series of Stock Acquisition Rights reflectedAnnual report
「The decrease of 13,954 treasury shares resulted from requests to purchase additional odd-lot shares for 54 shares and the exercise of stock acquisition rights for 13,900 shares.」
The Company disclosed that 13,900 shares of the stock compensation stock acquisition rights, including the 9th Series, were exercised during the period. - FY2022-Q2RestatedAnnual report
「Date of resolution: 13 May 2021; category and number of grantees (people): directors of the Company (excluding outside directors), 7; number of stock acquisition rights (rights): 78; class, description and number of shares underlying the stock acquisition rights (shares): common shares, 7,800; exercise period: 10 June 2021 to 9 June 2061」
The information on the 9th Series of Stock Compensation Stock Acquisition Rights is reiterated: 7 eligible directors, 78 rights, 7,800 shares and the exercise period. - FY2021AdvancedAnnual report
「9th Series of Stock Compensation Stock Acquisition Rights (Note 7) Date of resolution 13 May 2021 Category and number of grantees Directors of the Company (excluding outside directors) 7 people Number of stock options by class of shares Common shares: 7,800 shares」
Following the 8th Series, the Company disclosed a resolution on the offering terms for the 9th Series of Stock Compensation Stock Acquisition Rights, representing 7,800 shares, to 7 directors. - FY2020AdvancedAnnual report
「8th Series of Stock Compensation Stock Acquisition Rights (Note 7) Date of resolution 14 May 2020 Category and number of grantees Directors of the Company (excluding outside directors) 6 people Number of stock options by class of shares Common shares: 5,900 shares」
Following the 7th Series, the Company disclosed a resolution on the offering terms for the 8th Series of Stock Compensation Stock Acquisition Rights, representing 5,900 shares, to 6 directors. - FY2019AdvancedAnnual report
「7th Series of Stock Compensation Stock Acquisition Rights (Note 7) Date of resolution 15 May 2019 Category and number of grantees Directors of the Company (excluding outside directors) 7 people Number of stock options by class of shares Common shares: 9,000 shares」
Following the 6th Series, the Company disclosed a resolution to issue the 7th Series of Stock Compensation Stock Acquisition Rights, representing 9,000 shares, to 7 directors. - FY2019-Q2AchievedAnnual report
「The stock acquisition rights issued during the second quarter accounting period are as follows: 6th Series of Stock Compensation Stock Acquisition Rights」
The Company disclosed the issuance of 87 rights in the 6th Series of Stock Compensation Stock Acquisition Rights, representing 8,700 underlying shares. - FY2018AdvancedAnnual report
「At a meeting of the Board of Directors held on 16 May 2018, the Company approved the following offering terms for stock acquisition rights to be issued to its directors.」
Following the issuance of the 5th Series of Stock Compensation Stock Acquisition Rights, the Company approved the issuance of 87 rights in the 6th Series to 8 directors. - FY2018-Q2First statedAnnual report
「The stock acquisition rights issued during the second quarter accounting period are as follows: 5th Series of Stock Compensation Stock Acquisition Rights」
The Company issued 80 stock compensation stock acquisition rights approved on 17 May 2017, representing 8,000 underlying shares. The exercise period runs from 13 June 2017 to 12 June 2057, and the rights are subject to conditions on exercise following loss of director status.